Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Katie E CopleyDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0422-7475
Megan M DykstraNeuroscience Graduate Program, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-4551-2478
Morgan R MillerNeuroscience Graduate Program, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-3740-8144
Miriam LinsenmeierDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9795-9012
Longsheng LaiDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yuanhang WangDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yi-Wei ChangDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-2391-473X
Sami J BarmadaNeuroscience Graduate Program, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9604-968X
James ShorterDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-5269-8533
Funding
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Research Education ComponentP30AG072931 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott ROBERTS · 2021 to 2026
$26.5M
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degenerationR01NS097542 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARMADA, SAMI · 2016 to 2025
$3.8M
Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.RF1AG090910 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DONNELLY, CHRISTOPHER JAMES, KALB, ROBERT G · 2025 to 2025
$3.4M
Structural biology and molecular biophysics training programT32GM132039 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ben E. Black, Elizabeth Rhoades · 2019 to 2026
$3.3M
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALSR01NS113943 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARMADA, SAMI · 2020 to 2024
$1.9M
Regulation and impact of shortened TDP43 isoforms in FTD and ALSR37NS113943 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARMADA, SAMI · 2025 to 2025
$1.8M
Molecular Mechanisms and Evolution of the Rhoptry Secretion SystemR35GM156396 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI YI-WEI CHANG · 2025 to 2026
$957k
Linking Single-Cell Transcriptomic, Morphological, and Temporal Signatures of Vulnerability in NeurodegenerationR01NS148028 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sami Barmada, Joshua Welch · 2026 to 2026
$602k
Spatiotemporal analysis of TDP-43 toxicity and endolysosomal turnover mechanismsR56NS128110 · NINDS · UNIVERSITY OF ARIZONA · PI BARMADA, SAMI, BUCHAN, JOHN ROSS · 2022 to 2022
$393k
Developing RNA therapeutics for TDP-43 proteinopathy in ALS/FTDF31NS129101 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI COPLEY, KATIE ELIZABETH · 2022 to 2024
$131k
Identifying the function of alternatively spliced TDP43 isoforms and contribution to diseaseF31NS134123 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DYKSTRA, MEGAN · 2023 to 2024
Prion-like domain (PrLD)-mediated aggregation and concomitant dysfunction of the essential RNA-binding protein transactive response (TAR) DNA-binding protein of 43 kilodaltons (TDP-43) is a common feature of multiple debilitating neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). However, shortened TDP-43 (sTDP-43) splice isoforms where the PrLD is largely replaced by an 18-residue carboxyl-terminal tail also contribute to ALS pathophysiology and are enriched in motor neurons. Curiously, despite lacking most of the PrLD, sTDP-43 exhibits pronounced insolubility in cells and tissue of patients with ALS. Here, we establish that the short, isoform-specific carboxyl-terminal tail of sTDP-43 confers high aggregation propensity, which is encoded by two clusters of steric zippers, and can be mitigated by short RNA chaperones. Disrupting these zippers enhances sTDP-43 solubility at the pure protein level and in neurons. Notably, these steric zippers, rather than a predicted nuclear export signal in the carboxyl-terminal tail, drive cytoplasmic mislocalization and aggregation of sTDP-43 in neurons. Thus, we define the sequence-encoded determinants of aberrant sTDP-43 assembly and provide mechanistic insights into sTDP-43 disease pathology.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43. · full record | OpenQuestion